UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000036013 |
|---|---|
| Receipt number | R000041023 |
| Scientific Title | The effect of tofogliflozin on body fat volume |
| Date of disclosure of the study information | 2019/04/01 |
| Last modified on | 2019/02/26 16:55:15 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The effect of tofogliflozin on body fat volume
Acronym
tofogliflozin for body fat
Scientific Title
The effect of tofogliflozin on body fat volume
Scientific Title:Acronym
tofogliflozin for body fat
Region
| Japan |
Condition
Condition
Type 2 diabetes
Classification by specialty
| Cardiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To clarify the effects of tofogliflozin on body fat volume including visceral, subcutaneous, and epicardial fat
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Epicardial Adipose Tissue Thickness,HbA1c6 month after the treatment
Key secondary outcomes
body weight, voluem of visceral fat, subcutaneous fat, skeletal muscle
Base
Study type
Interventional
Study design
Basic design
Single arm
Randomization
Non-randomized
Randomization unit
Blinding
Open -no one is blinded
Control
Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
1
Purpose of intervention
Treatment
Type of intervention
| Medicine |
Interventions/Control_1
Administration of 100 mg of tofogliflozin for 6 month
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Type 2 diabetes
Key exclusion criteria
Hypersensitivity to canagliflozin, Complicated with sever ketoacidosis, diabetic coma, Type 1 diabetes, Complicated with severe infection, sever trauma
Target sample size
15
Research contact person
Name of lead principal investigator
| 1st name | |
| Middle name | |
| Last name | Shusuke Yagi |
Organization
Department of Cardiovascular Medicin
Division name
Department of Community Medicine and Human Resource Development
Zip code
Address
3-18-15 Kuramoto-cho Tokushima-city
TEL
088-633-7851
syagi@tokushima-u.ac.jp
Public contact
Name of contact person
| 1st name | |
| Middle name | |
| Last name | Shusuke Yagi |
Organization
The University of Tokushima Graduate School of Health Biosciences
Division name
Department of Community Medicine and Human Resource Development
Zip code
Address
3-18-15 Kuramoto-cho Tokushima-city
TEL
088-633-7851
Homepage URL
syagi@tokushima-u.ac.jp
Sponsor or person
Institute
Tokushima University Graduate School
Institute
Department
Personal name
Funding Source
Organization
NA
Organization
Division
Category of Funding Organization
Self funding
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Address
Tel
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2019 | Year | 04 | Month | 01 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Preinitiation
Date of protocol fixation
| 2019 | Year | 03 | Month | 01 | Day |
Date of IRB
Anticipated trial start date
| 2019 | Year | 05 | Month | 01 | Day |
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2019 | Year | 02 | Month | 26 | Day |
Last modified on
| 2019 | Year | 02 | Month | 26 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041023
